* Icad - On Dec 16, 2016, co entered into an asset purchase agreement between company and Invivo Corporation - SEC filing
* Harbert Discovery Fund LP reports 5.01 percent stake in Icad Inc as of Nov. 7 - SEC filing
* Kevin Burns, president, chief financial officer and chief operating officer, is resigning from company effective September 23, 2016
* Company is not providing financial guidance at this time Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
iCAD (ICAD +5.8%) Q2 results: Total Revenues: $9.7M (+25.4%); Gross Profit: $6.8M (+30.8%); Operating Expenses: $7.0M (+22.8%); Operating Loss: ($166K) (+64.9%); Net Loss: ($997K) (+47.0%); Loss Per Share: ($0.07) (+58.8%); Quick Assets: $34.9M (+193.3%); CF Ops: ($2.3M) (-224.0%).2H 2014 Guidance: Revenues: $23M - 25M; adjusted EBITDA margin: 10 - 15%. Post your comment!
Top 10 Gainers: ZIPR +122%. NEWL +89%. UBIC +37%. NLST +23%. AMSC +22%. ICAD +21%. OTCQB:AMTX +18%. BIOF +18%. TWX +16%. TSEM +12%.Top 10 Losers: ININ -16%. BIOA -15%. ALDX -15%. LCI -14%. IGC -10%. EVI -9%. BBRY -9%. IMUC -8%. MILL -8%. DGSE -8%. 6 comments!
Top 10 Gainers: MBLX +38%. VIFL +27%. BLDP +22%. PSUN +23%. CLWT +21%. PRIS +21%. EVI +16%. TRIT +16%. AGX +15%. ICAD +15%. Top 10 Losers: RALY -22%. ULTA -20%. SEAC -18%. BIG -14%. SOL -10%. GIG -9%. LPTH -10%. UPI -7%. NCQ -10%. CALI -8%. Post your comment!
iCAD (ICAD +4.7%) adds the title of COO to CFO Kevin Burns' list of responsibilities. He will lead all operational functions of the company.As CFO, Burns has guided iCAD on a consistent string of better-than-expected quarters. Post your comment!
Спайдер повышается перед открытием торгов на NYSE. Европейские индексы на положительной территории. SPY (внутридневной график) рост на премаркете. Поддержка 176.20 Премаркет NYSE/NASDAQ: Повышаются на премаркете: • In reaction to strong earnings/guidance: ONP +21.1% (light volume), NTRI +12.5%, DATA +9.2% (also files registration statement for proposed secondary offering), NOK +7.3%, XYL +7.2%, CIE +5.5%, BP +4.9%, MAS +4.7%, AMKR +3.5%, ICON +3.1%, ACT +2.8%, PRE +2.5%, (light volume), HIG +2.4%, ALLT +2.3%, LINE +1.8%, VLO +1.7%, MIC +1%, ACI +0.7%, JCI +0.6%, GGP +0.5%, (light volume), PBI +0.5%, (light volume), AAPL +0.4%, OXY +0.3%. • M&A news: LCC +5% (AMR, US Airways & the US Government have agreed to go to mediator to find a resolution in the antitrust case, according to reports ), BTH +3.2% (saw late spike — attributed to reports of CVSL offer). • Select oil/gas related names showing strength boosted by BP earnings: RDS.A +1%, STO +0.7%, TOT +0.6%. • European drug names are higher: GSK +0.8%, NVS +0.8% • Other news: IBN +5% and HDB +1.3% (India rate news), KORS +4.3% (to join the S&P500), ALU +3.1% (ahead of earnings later this week, NOK also reported), GLUU +3.1% (continued strength), ITUB +2.1% (still checking), STM +1.6% (still checking), TSLA +1.6% (not seeing anything specific), TLM +1% ( Icahn discloses 6.96% stake, up from 5.97% stake reported on Oct 7), DAL +1% (on LCC / AAMRQ news) LL +0.9% (following positive mention on MadMoney), GPS +0.8% (Lone Pine Capital discloses 5.4% passive stake in 13G filing), BMY +0.4% (Barron's profiles positive view on Bristol-Myers), TSCO +0.3% (following positive mention on MadMoney). • Analyst comments: ONTX +1.9% ( upgraded to Buy from Neutral at Citigroup), YHOO +0.8% (upgraded to Outperform from Market Perform at Bernstein), GME +0.5% (initiated with a Buy at Stifel) Снижаются на премаркете: • In reaction to disappointing earnings/guidance: VOLC -16.7% (also several downgrades), PMCS -10.4%, PSMI -6.9%, ECOM -6.5%, (also ChannelAdvisor Announces Proposed Follow-On Offering), UBS -5.5%, CMI -5.1%, ETR -4.9%, (light volume), ARR -4.8%, STX -4.1%, ICAD -3.8%, SANM -3.8%, (light volume), AGNC -3.6%, DDD -3.1%, IVR -2.4%, (light volume), GT -2.1%, LYB -2%, X -1.8%, DB -1.7%, PCL -1.3% (also announces public offering of 14.1 mln shares of common stock), AET -1.3%, HLF -1%. • Select metals/mining stocks trading lower: NEM -2.5%, GOLD -2.4%, RIO -0.9%, GLD -0.7%, GG -0.7% (downgraded to Neutral from Overweight at HSBC), GFI -0.6%, SLW -0.5%, SLV -0.4%. • Other news: CLSN -14.5% ( announces 1 for 4.5 reverse stock split), EROC -4.8% (decreases quarterly distribution ~32% to $0.15 from $0.22 per unit; sees Q3 adjusted EBITDA of $62.8 mln, downgraded to Neutral from Buy at BofA/Merrill ), SHO -3.4% (announces public offering of 20,000,000 shares of common stock), CLNY -2.9% (announces public offering of 10 mln shares of common stock ), ERJ -2.7% (still checking), RBS -2.6% (still checking), FNB -2.2% (announces capital action plan and commences $50 million common stock offering), SSYS -2% (on DDD results), SLG -1.2% (announces proposed offering of 2.6 mln shares of common stock), RCL -0.9% (still checking), BKU -0.7% ( prices 9 mln shares of its common stock by selling shareholders at $30.75 per share), NYX -0.5% (KORS replcing in S&P 500),. • Analyst comments: CYOU -0.2% (downgraded to Hold from Buy at Brean) Отчеты компаний: Сегодня перед открытием: ACI ACT ADM AET AGCO AGN ALR AME AMTD APD AVX CAS CBR CCBG CCMP CIE CMI CMLS CNX CRS CRVL CRY CVLT CYNO DAN DDD DHX DIN DORM ECL ETR EXAS FDP FIS FLWS GK GOV GT HBCP HCP HRS HSII HUN ICON IIVI ISSI IVR JBLU JCI LBY LCAV LLL LYB MDC MWV NCI OXY PAG PBI PFE PROV RTIX SCBT SCHN SCOR SFI SNH SPAR ST STBA SUI TRW UDR UTHR VLO VRTX VSH WDR WM X XRAY XYL Вчера после закрытия: ARLP AWI BIIB BKW BOH BWP CNA CYOU DCOM EDR EW HAE KEX L MCY ONB ROP SBCF SOHU STNG TEN TGE TRS UFPT Интересные новостные акции NYSE и NASDAQ: • DATA – шорт ниже 68.00 • CIE – лонг выше максимума премаркета, шорт ниже 24.00 • HIG – лонг выше максимума премаркета • VLO – лонг выше максимума премаркета • STX – лонг выше максимума премаркета • DDD – лонг выше 56.00 • LYB – шорт ниже минимума премаркета Оригинал статьи: shark-traders.com/blog/analitika-nyse-na-29-oktyabrya/
By Inflection Point Investing LLC: We believe iCAD, Inc. (ICAD), a provider of innovative cancer detection and targeted therapy solutions, has the potential to double over the next twelve months and triple by the end of 2015. Multiple near-term catalysts will accelerate iCAD's top-line growth and position the company to return to GAAP profitability in the next 2-3 quarters, potentially as early as Q4. Given that iCAD's stock is cheap by various valuation metrics, undiscovered, and under-owned, we feel strongly that shares have minimal downside and substantial upside into both year-end and also throughout both 2014 and 2015.iCAD is reminiscent of CalAmp (CAMP) circa 2012. We alluded to this in our first article on iCAD earlier this year when the stock was trading in the mid-$4s.In particular, iCAD shares many of the same attributes that provided the foundation for CalAmp's turnaround over two years ago:- A legacy business poised to turn Complete Story »
Top 10 Gainers: CAFI +48%. KUTV +25%. AMCF +22%. ICAD +20%. VG +17%. GSE +17%. SKBI +17%. ACAD +14%. ECTE +14%. GALT +13%.Top 10 Losers: RT -17%. CTXS -11%. PRXI -11%. WPCS -10%. SPCB -10%. DRWI -9%. PRTS -8%. RGP -8%. ESEA -7%. CWTR -7%. Post your comment!
Top 10 Gainers: OINK +37%. MW +29%. VISN +21%. ALTI +18%. KUTV +16%. CERE +14%. CALD +14%. URRE +12%. MG +11%. ICAD +10%.Top 10 Losers: ARIA -70%. LRN -37%. PVG -26%. CYTR -20%. LPTN -19%. LAS -18%. FATE -18%. PBYI -15%. ATOS -14%. OPXA -13%. Post your comment!
iCAD (ICAD +2.3%) shares jump after the company presents positive 3-year data for non-melanoma skin cancer treatment efficacy of its Xoft System at the American Society of Radiation Oncology's annual meeting.The study showed "good cosmesis, low toxicity levels and no recurrences" across a 187 patient cohort. Post your comment!
iCAD (ICAD): Q1 EPS of -$0.07 beats by $0.18. Revenue of $7.93M beats by $0.73M. (PR) Post your comment!
iCAD ([[ICAD]] +2.3%) FDA) gains after saying it's received FDA clearance for its new cervical applicator for use with its Xoft Axxent Electronic Brachytherapy System to deliver high dose rate brachytherapy for intracavitary treatment of cancer of the uterus and cervix.
iCAD (ICAD +2.3%) FDA) gains after saying it's received FDA clearance for its new cervical applicator for use with its Xoft Axxent Electronic Brachytherapy System to deliver high dose rate brachytherapy for intracavitary treatment of cancer of the uterus and cervix. Post your comment!